# Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD

> **NCT06707753** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Beijing Anlong Biopharmaceutical Co., Ltd.** · enrollment: 21 (estimated)

## Conditions studied

- Wet Age-related Macular Degeneration (wAMD)

## Interventions

- **DRUG:** AL-001

## Key facts

- **NCT ID:** NCT06707753
- **Lead sponsor:** Beijing Anlong Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-11
- **Primary completion:** 2025-08-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06707753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06707753, "Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06707753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*